LENZ Therapeutics, Inc. (LENZ)
USD 29.24
(-9.78%)
USD 29.24
(-9.78%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | 15 Million | - | - | - |
| Cost of Revenue | 2.4 Million | 8.34 Million | 734 Thousand | 121 Thousand | - |
| Gross Profit | -2.4 Million | 6.65 Million | -734 Thousand | -121 Thousand | - |
| Operating Expenses | 70.7 Million | 97.29 Million | 59.7 Million | 13.37 Million | 29 Thousand |
| Selling, General and Administrative Expenses | 40.97 Million | 32.85 Million | 21.77 Million | 4.25 Million | 29 Thousand |
| Research and Development Expenses | 29.73 Million | 64.44 Million | 37.93 Million | 9.12 Million | - |
| Other Expenses | - | 19 Thousand | -869 Thousand | - | - |
| Cost and Expenses | 73.11 Million | 105.63 Million | 60.44 Million | 13.5 Million | 29 Thousand |
| Operating Income | -73.11 Million | -105.63 Million | -60.44 Million | -13.5 Million | -29 Thousand |
| Interest Expense | - | - | - | 40 Thousand | 80 Thousand |
| Income Tax Expense | -124.65 Million | 347 Thousand | 497.44 Thousand | - | -171.86 Thousand |
| Earnings before Tax | -124.65 Million | -101.05 Million | -70.76 Million | -68.37 Million | -109 Thousand |
| Net Income | -124.65 Million | -101.05 Million | -70.76 Million | -68.37 Million | -109 Thousand |
| Earnings Per Share Basic | -15.30 | -12.89 | -8.54 | -8.24 | -0.01 |
| Earnings Per Share Diluted | -15.30 | -12.89 | -8.54 | -8.24 | -0.01 |
| Weighted Average Shares Outstanding | 8.14 Million | 7.83 Million | 8.28 Million | 8.29 Million | 8.29 Million |
| Weighted Average Shares Outstanding (Diluted) | 8.14 Million | 7.83 Million | 8.28 Million | 8.29 Million | 8.29 Million |
| Gross Margin | - | 0.44 | - | - | - |
| EBIT Margin | - | -6.49 | - | - | - |
| Profit Margin | - | -6.74 | - | - | - |
| EBITDA | -122.24 Million | -97.29 Million | -70.02 Million | -68.21 Million | -29 Thousand |
| Earnings Before Tax Margin | - | -7.04 | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 18 Thousand | 5000.00 | 142 Thousand | 2.4 Million | 800 Thousand | 2.09 Million |
| Gross Profit | -18 Thousand | -5000.00 | -142 Thousand | -2.4 Million | -800 Thousand | -2.09 Million |
| Operating Expenses | 14.33 Million | 16.08 Million | 14.46 Million | 70.7 Million | 12.87 Million | 18.86 Million |
| Selling, General and Administrative Expenses | 7.38 Million | 5.55 Million | 14.45 Million | - | 10.49 Million | 5.35 Million |
| Research and Development Expenses | 6.94 Million | 10.53 Million | 1000.00 | - | 2.38 Million | 13.5 Million |
| Other Expenses | 1.63 Million | -1.34 Million | - | - | 1.23 Million | -18 Thousand |
| Cost and Expenses | 14.35 Million | 16.08 Million | 14.6 Million | 73.11 Million | 13.67 Million | 20.96 Million |
| Operating Income | -14.35 Million | -16.08 Million | -14.6 Million | -73.11 Million | -13.67 Million | -20.96 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | -788 Thousand | - | - | - | - |
| Earnings before Tax | -10.25 Million | -16.64 Million | -22.91 Million | -124.65 Million | -22.48 Million | -55.31 Million |
| Net Income | -10.25 Million | -16.64 Million | -22.91 Million | -124.65 Million | -22.48 Million | -55.31 Million |
| Earnings Per Share Basic | -0.40 | -3.53 | -2.77 | - | -2.75 | -6.82 |
| Earnings Per Share Diluted | -0.40 | -3.53 | -2.77 | - | -2.75 | -6.82 |
| Weighted Average Shares Outstanding | 25.6 Million | 4.71 Million | 8.28 Million | 8.14 Million | 8.17 Million | 8.1 Million |
| Weighted Average Shares Outstanding (Diluted) | 25.6 Million | 4.71 Million | 8.28 Million | 8.14 Million | 8.17 Million | 8.1 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -14.33 Million | -16.08 Million | -14.46 Million | - | -12.87 Million | -18.86 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
JTS
BYOGF
7284
1780
ROUTE
CRSR